Welcome to our dedicated page for Surgery Partners news (Ticker: SGRY), a resource for investors and traders seeking the latest updates and insights on Surgery Partners stock.
Surgery Partners, Inc. reports developments tied to its short-stay surgical facility network and outpatient delivery model. The company provides surgical and related ancillary care through ambulatory surgery centers, surgical hospitals, anesthesia services, multi-specialty physician practices and urgent care facilities, with revenue tied to patient care services and facility case activity.
Recurring SGRY news includes quarterly results, same-facility revenue and case trends, adjusted EBITDA and guidance, operational initiatives, portfolio optimization, acquisition activity, financing and leverage actions, share repurchase authorizations, board composition and shareholder communications involving the company’s strategic direction.
Surgery Partners (NASDAQ:SGRY) reported first quarter 2026 results for the period ended March 31, 2026. Revenue was $810.9 million, up 4.5% year-over-year; adjusted EBITDA was $102.3 million; net loss attributable to Surgery Partners was $35.9 million. The company reaffirmed 2026 guidance: revenue of $3.35B–$3.45B and adjusted EBITDA of at least $530 million. Cash and equivalents were $182.3 million and revolving credit capacity was $666.1 million. The company will host a conference call on May 5, 2026 at 8:30 a.m. ET.
Surgery Partners (NASDAQ:SGRY) will release first quarter 2026 results before the market opens on Tuesday, May 5, 2026, followed by a conference call at 8:30 a.m. ET. Live dial-in numbers, replay details and a webcast on the company's Investor Relations website are provided.
The replay will be available until May 19, 2026, and the company posts financial and material information on its website.
Surgery Partners (NASDAQ:SGRY) appointed Lloyd Dean to its Board of Directors on March 12, 2026. Mr. Dean is a former CEO of CommonSpirit Health and Dignity Health, a healthcare adviser to federal administrations, and currently serves on multiple corporate boards and as a Bain Capital senior advisor.
This addition brings national health system leadership experience aimed at supporting Surgery Partners' expansion of high‑value outpatient surgical care.
Ortelius Advisors delivered an open letter to Surgery Partners (NASDAQ: SGRY) stockholders on March 10, 2026, criticizing management and the board for poor performance and value destruction.
Ortelius cites a 67% five-year stock decline and proposes monetizing surgical hospitals to generate billions, repurchase shares, reduce debt, refresh the board, and refocus on ambulatory surgery centers to unlock intrinsic value.
Surgery Partners (NASDAQ:SGRY) will present at the Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10, 2026 at 2:30 p.m. ET.
Interested parties can listen via a simultaneous webcast through the company's investor relations website at www.surgerypartners.com. A replay will be available for a limited time.
Surgery Partners (NASDAQ: SGRY) acquired Preferred Vascular Group, an ambulatory surgical center operator focused on dialysis access procedures. PVG operates eight ASCs in Georgia and Ohio with 16 physicians and >160 employees. The deal gives Surgery Partners entry into the $6 billion dialysis access market with over two million procedures annually and retains PVG management to run the new operating entity.
Ziegler served as exclusive financial advisor to PVG; legal counsel included Benesch for PVG and McDermott for Surgery Partners.
Surgery Partners (NASDAQ:SGRY) reported fourth-quarter and full-year 2025 results and set 2026 guidance, while announcing a new share repurchase program. Full-year revenue rose to $3.3 billion (+6.2%) and Adjusted EBITDA reached $526.2 million (+3.5%).
The company posted a full-year net loss attributable to Surgery Partners of $77.9 million, finished the year with $239.9 million in cash and $692.8 million of revolver capacity, and authorized up to $200 million in share repurchases. 2026 guidance targets Adjusted EBITDA of at least $530 million and revenue of $3.35–3.45 billion (ex-M&A).
Surgery Partners (NASDAQ:SGRY) will release Q4 2025 results after market close on Monday, March 2, 2026, followed by a conference call on Tuesday, March 3, 2026 at 8:30 a.m. ET.
Live dial-in numbers, a webcast via the Investor Relations website, and a replay available through March 17, 2026 (passcode 13758530) were provided for investors and other parties.
Surgery Partners (NASDAQ:SGRY) priced an add-on offering of $425.0 million aggregate principal amount of 7.250% senior unsecured notes due 2032. The Issuer expects the offering to close on December 16, 2025, subject to customary closing conditions.
The Notes will be guaranteed by each domestic wholly-owned subsidiary that guarantees the Issuer’s senior secured credit facilities and will be issued as part of the same series as the $800.0 million of 7.250% senior notes due 2032 issued in April 2024. Surgery Partners intends to use net proceeds for general corporate purposes, including repaying borrowings under its revolving credit facility. The offering is being made under Rule 144A and Regulation S.
Surgery Partners (NASDAQ:SGRY) announced that subsidiary Surgery Center Holdings intends to offer an additional $425.0 million aggregate principal amount of its 7.250% senior unsecured notes due 2032, to be issued as part of the same series as the April 2024 notes.
The Notes will be guaranteed on a senior unsecured basis by each domestic wholly owned subsidiary that guarantees the issuer’s senior secured credit facilities. Net proceeds are intended for general corporate purposes, including possible repayment of outstanding borrowings under the company’s revolving credit facility. The offering will be limited to qualified institutional buyers (Rule 144A) in the U.S. and non-U.S. persons under Regulation S, and the Notes will not be registered under the Securities Act.